Key result
Synthetic heparin glycopolymers match clinical anticoagulants in prolonging plasma clotting times.
Not to clot: Heparin and its low-molecular-weight derivatives are clinical therapeutics used to treat and prevent blood clots. The synthesis of heparin-based glycopolymers that are potent and potentially safer mimetics of heparin is described. The mimetics exhibited activity against proteases (FXa and FIIa) in the coagulation cascade and prolonged blood clot times in human plasma with efficacies similar to those of clinical anticoagulants. ATIII=antithrombin III.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2013) studied blood clots. heparin-based glycopolymers vs. clinical anticoagulants was evaluated on activity against proteases (FXa and FIIa) and blood clot times in human plasma. Synthesized heparin-based glycopolymers exhibited activity against coagulation proteases and prolonged blood clot times in human plasma with efficacies similar to clinical anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: